Connective tissue repair implant maker Miach Orthopaedics announced that it named Stephen Wohlert as its new vice president of manufacturing.
A 15-year veteran of the medical device and over-the-counter drug concept and product development space, Wohlert recently served as the director of research & development at Professional Disposable International. He also held the same position at Medtronic/Covidien and was a project leader at Ethicon Norderstedt, according to a news release posted yesterday.
Wohlert is slated to lead Westborough, Mass.–based Miach’s manufacturing and platform innovation efforts for its Bridge-Enhanced ACL repair (BEAR) implant for anterior cruciate ligament repair.
“Stephen is an experienced leader with a successful track record of transferring concepts to product development and commercialization,” Miach Orthopaedics president & CEO Martha Shadan said in the news release. “His unique expertise in collagen processes will be invaluable not only for overseeing manufacturing of the BEAR implant as a treatment for ACL repair, but also for further innovating the platform technology.”
BEAR stands for bridging scaffold-enhanced ACL repair. It’s a bio-engineered bridging scaffold designed to facilitate the healing of a torn ACL by restoring normal anatomy and function to the knee. Currently, the company completed enrollment for the FDA-approved BEAR II pivotal trial.
The National Football League Players Assn. contributed to a nearly $23 million Series A round for the BEAR implant in September 2018.